Press Release

Daewoong Pharmaceutical’s press release

NEW 1 Daewoong, Q1 is just early stage of better performance: 2021-0506

NEW 2 Daewoong Pharmaceutical Signs Agreement to Export Fexuprazan, A New Drug for Gastroesophageal Reflux Disease, to China: 2021-0318

NEW 3 Daewoong Pharmaceutical obtains authorization for manufacturing ATMPs... Entering the CDMO business: 2021-0114

Daewoong, Q1 is just early stage of better performance 2021-05-06
Daewoong Pharmaceutical Signs Agreement to Export Fexuprazan, A New Drug for Gastroesophageal Reflux Disease, to China 2021-03-18
Daewoong Pharmaceutical obtains authorization for manufacturing ATMPs... Entering the CDMO business 2021-01-14
Daewoong Pharmaceutical’s Olostar confirmed better effect than co-administration of individual drugs 2021-01-06
Daewoong Pharmaceutical’s gastroesophageal reflux disease drug Fexuprazan obtained approval for a phase-3 trial in China 2020-12-30
Daewoong Pharmaceutical’s Nabota proves its efficacy in hair loss through clinical trials 2020-11-25
Daewoong Pharmaceutical’s Foistar Tab expected to be released as treatment for COVID-19 in January 2021 2020-11-23
Daewoong Pharmaceutical’s subsidiary iN Therapeutics begins development of hearing loss treatment with AI drug company DEARGEN Inc. 2020-11-17
Daewoong Pharmaceutical’s Olostar proved its excellent blood pressure reduction effects… Published in an SCI-grade journal 2020-11-11

1 2 3 4 5 6 7 8 9 10 다음 페이지

Search